A survey of 358 patients with primary antibody deficiency shows that mycoplasmal infection is the commonest cause of severe chronic erosive arthritis. We review our experience with 18 patients with confirmed or probable mycoplasmal arthritis. There was a broad spectrum of severity from a monoarthritis rapidly responding to tetracyclines to severe debilitating polyarthritis, sometimes with antibiotic-resistant organisms which in two cases were eliminated following hyperimmune animal serum therapy. Most patients had very low serum IgG levels at the onset of arthritis, suggesting that maintaining levels within the normal range with immunoglobulin replacement may prevent infection. The unique susceptibility of these patients to mycoplasmal arthritis shows that antibodies play a crucial role in protection against these organisms.
F 1970 to 1987, clinical data from nearly all patients diagnosed with primary antibody deficiency in the South of England were collected by the MRC Immunodeficiency Clinic (Clinical Research Centre, Harrow), and most of the adult patients were referred to the clinic for assessment and advice. From 1987, some adult patients were managed locally, although most patients in the UK with chronic arthritis were referred at some stage to our clinic for advice. This allows a reasonable estimate of the prevalence of arthritis in this group of patients. Between 1970 and 1996, a total of 358 patients with either common variable immunodeficiency (CVI) or X-linked agammaglobulinaemia (XLA) have been studied. Although acute bacterial septic arthritis is a rare presenting feature in these patients [1] , no patient has developed a confirmed bacterial arthritis following regular immunoglobulin replacement therapy, either given i.m. or i.v. This paper describes our experience of 18 patients with primary antibody deficiency who developed a chronic arthritis which in the majority was confirmed as being caused by mycoplasmas. Some aspects of these cases have previously been published as anecdotal case reports; however, we now provide the first clinical overview of mycoplasmal arthritis, with emphasis on the difficulties of treatment and diagnosis, and the long-term prognosis.
PATIENTS AND METHODS From a total of 358 patients (306 with CVI and 52 with XLA), 19 presented with severe chronic arthritis with effusions in whom routine culture of synovial fluid or biopsy of synovial tissue failed to identify bacteria.
One of these had features consistent with chronic rheumatoid arthritis and has been reported elsewhere [2] . Of the remaining 18 patients, seven had XLA, defined as onset of symptoms in early childhood and Q1% circulating B lymphocytes; the diagnosis was confirmed in four of these patients by genotyping [3] . Eleven patients had CVI, the diagnostic criteria being primary panhypogammaglobulinaemia at the time of diagnosis, without evidence of X-linked inheritance and the presence of circulating B cells [4] . In most patients, mycoplasmal infection was confirmed by culturing the organisms directly from synovial fluid or synovial biopsy, but several patients were included in whom the clinical presentation and the course of the illness strongly suggested mycoplasmal arthritis, even though this could not be confirmed by a positive culture.
Microbiological screening and antibiotic sensitivity testing
All samples of synovial fluid and biopsy material were collected in sterile containers and delivered within an hour to a routine microbiological laboratory to be cultured for bacteria. Other portions of the samples were examined for ureaplasmas and mycoplasmas as follows. Synovial tissue samples were homogenized in a standard liquid medium in a Ten-Broeck tissue grinder to produce a 10% w/v suspension. Details of this medium have been described previously [5] . In brief, liquid medium comprised 70% PPLO broth (Difco) to which was added 10% yeast extract (25% w/v), 20% horse serum, 1000 IU/ml of penicillin, 0.05% thallium acetate and 0.002% phenol red. To this medium was added one of the following substrates and the pH adjusted as indicated to provide three separate media for the attempted isolation of glucose-fermenting and arginine-hydrolysing mycoplasmas and ureaplasmas, respectively: 1% glucose (pH 7.8), 2% -arginine hydrochloride (pH 7.0) or 1% urea (pH 6.8).
Serial 10-fold dilutions of specimens (0.2 ml in 1.8 ml of medium) were made to a dilution of 10 −6 in ureaplasmal medium and to 10 −8 in mycoplasmal media. The cultures were incubated at 37°C for up to 6 weeks during which time a change in colour of the medium indicated growth of organisms. Ureaplasmas and mycoplasmas were identified by using specific antisera in a metabolism-inhibition test [6] and antibiotic sensitivities were determined by using the same technique [7] .
RESULTS

Clinical features
These are shown in Table I for the seven XLA and the 11 CVI patients. Most XLA patients were diagnosed as having this condition between 1 and 4 yr of age, but in two the diagnosis was not made until they were 9 and 13 yr old. All had serum IgG levels below 2 g/l at the time of diagnosis, and prior to replacement immunoglobulin therapy. Mycoplasmal arthritis was the presenting feature in three XLA patients. Two patients were on i.m. immunoglobulin replacement therapy prior to the onset of arthritis, since i.v. preparations were not generally available in the UK before 1985. Two patients were receiving i.v. replacement therapy before the onset of arthritis, one of whom was an irregular attender who had a serum IgG level below the normal range (i.e. 5.1 g/l).
In the CVI group, most patients were diagnosed as having this deficiency in the third to fifth decades of life. Three patients were being treated with i.v. immunoglobulin before the onset of arthritis, but in two the serum IgG trough level was below the normal range. The third patient had a trough level in the normal range, but he had a splenectomy in childhood for thrombocytopenia which might have made him more susceptible to systemic mycoplasmal infection.
Manifestations of arthritis
The joints involved in the arthritis and the organisms isolated are listed in Table IIa and b. Some examples of gross pathology are shown in Fig. 1 . Most patients presented with a monoarthritis, usually involving the knee, shoulder, elbow or hip. If diagnosis and adequate treatment were delayed, then more widespread disease often developed and involved many joints. The finger joints were not usually affected, but the appearances sometimes mimicked rheumatoid arthritis. The wrist, carpal and metacarpal joints were severely affected in two patients with extensive infection. The joint fluid was usually yellow and turbid or purulent, but occasionally there was a relatively clear fluid containing only a few neutrophils. Mycoplasma pneumoniae, Mycoplasma hominis and Ureaplasma urealyticum were the species commonly isolated from synovial fluid. In one case, Mycoplasma salivarium was isolated, a species not considered pathogenic in immunocompetent individuals.
Extra-articular manifestations
None of the patients were systemically ill at presentation, in contrast to the usual clinical picture in acute bacterial septic arthritis. Most of the patients with monoarthritis were afebrile or had a fluctuating low-grade fever, and a neutrophil leucocytosis was unusual. Systemic effects were minor in the three patients who developed polyarthritis and most of the clinical problems were related to side-effects of the Table I . R, right; L, left; MTP-I, first metatarsal phalangeal joint; MCP-I, first metacarpal phalangeal joint; PIP-I, first proximal interphalangeal joint; an * in the second column denotes the first joint affected, if there was a clear interval before other joints were involved; nd, not done; nil, negative culture for mycoplasmas and ureaplasmas; all specimens negative on routine bacterial cultures; †nodules on upper ulnar prominence; ‡isolated from synovial tissue; §'sterile', standard microbiological culture negative, mycoplasmal culture not done; ¶gross appearance of synovial fluid when this could be obtained; unless stated fluid contained predominantly polymorph leucocytes; (P), purulent. various antibiotics used. Three patients had s.c. nodules over the upper ulnar borders of the forearms, similar to those associated with rheumatoid arthritis, which disappeared with successful treatment of the arthritis.
Treatment and prognosis
Patients could be divided into three groups according to their clinical progress (Table IIIa and b) . Five patients (nos 2, 3, 8, 11 and 17) were diagnosed during the first few weeks as having a mono-or polyarthritis which responded rapidly to tetracycline combined with i.v. immunoglobulin replacement therapy. No organism was cultured from two of these patients (no. 2 whose arthritis failed to respond to ciprofloxacin and no. 17 who failed to respond to amoxycillin, gentamicin and ciprofloxacin), but the rapid response to tetracycline supports a diagnosis of mycoplasmal infection. These patients had no permanent joint damage. One patient (no. 2) had a single relapse and needed further treatment for 3 months to achieve a complete remission.
The second group comprised 10 patients in whom the diagnosis was delayed and/or who responded initially to tetracycline, but then had relapsing disease which responded to further courses of antibiotics (nos 1, 5, 6, 10, 12, 13, 14, 15, 16 and 18) . Five of these patients (nos 10, 12, 14, 15 and 18) were left with permanent joint damage, sometimes leading to severe disability.
The third group comprised three patients who had widespread infection with tetracycline-resistant organisms (nos 4, 7 and 9). These patients were difficult to manage and various combinations of antibiotics were used, depending on sensitivity testing, although it was not clear whether the treatment influenced the progression of the joint disease. There were also significant side-effects from some of the antibiotics. Surgical intervention, e.g. drainage of joint effusions, was not helpful and patients nos 4 and 7 developed soft-tissue infection with sinus formation. Both of them also sustained widespread joint damage resulting in severe disability, even though a complete remission was achieved following treatment with hyperimmune goat serum. The third patient (no. 9) is currently severely incapacitated with multiple joint disease, and is about to receive hyperimmune rabbit serum therapy. The sequence of events for patients 4 and 7 is outlined in Tables IV and V. DISCUSSION Mycoplasmal septic arthritis is confined mainly to patients with primary antibody deficiency. There have been descriptions of mycoplasmal arthritis and septicaemia in patients following severe trauma or with other debilitating disease [8] [9] [10] , but in most of these cases the possibility of antibody deficiency had not been investigated. We are not aware of reports of mycoplasmal arthritis in secondary immunoglobulin deficiency, as occurs commonly in chronic lymphatic leukaemia or myeloma. Those patients particularly prone to mycoplasmal arthritis have severe immunoglobulin deficiency associated with either CVI or XLA. Eleven of the 12 patients in this series who developed infection while on immunoglobulin replacement therapy had levels of serum IgG below the lower limit of the normal range for adults (i.e. 8.0 g/l), and seven had been on i.m. immunoglobulin with levels below 4.0 g/l. When screening batches of immunoglobulin for antibodies to the ureaplasmal strain isolated from patient no. 7, we found low titres ranging from 1:4 to 1:32. It is our current practice to maintain a minimum IgG trough level of 8.0 g/l in an attempt to provide a reasonable level of specific antibody. This approach will need to be validated in the future by comparing the incidence of mycoplasmal arthritis in our clinic and in others who accept a lower minimum trough level.
Fortunately, most patients with mycoplasmal arthritis respond to tetracyclines. A review of cases reported by others in the literature confirms that high-dose i.v. doxycycline is usually effective [11] [12] [13] [14] [15] [16] [17] . However, i.v. doxycycline is no longer licensed in Europe, but can be obtained for specific patients (Pfizer). Once the infection is under control, our experience shows that prolonged courses of oral doxycycline are indicated, probably for not less than 12 weeks.
Because mycoplasmas are the most common cause of arthritis in patients with primary immunodeficiency, antibiotic treatment should not be delayed while waiting for results of cultures. Although most of the effusions were purulent, there were exceptions. Improvement of the joint is usually seen within 1 week of starting i.v. tetracycline therapy, or within 2 weeks with oral therapy. A minority of patients fail to respond because they have mycoplasmas that are resistant to tetracyclines, and the three patients in our series with resistant organisms were left with severe disability. Various antibiotics were used, but there was a poor response even when the organisms appeared to be sensitive in vitro to a particular drug. This may have been due to infection with multiple strains with differing sensitivities, or the rapid emergence of strains resistant to a particular antibiotic. There was a strong clinical impression that treatment with hyperimmune animal serum cleared the infection in two of the most severely affected patients. When a joint is irreversibly damaged with no evidence of ongoing infection, then joint replacement should be considered; we have seen no recurrence of infection in prosthetic joints.
Six patients were incorrectly diagnosed and treated for rheumatoid or reactive arthritis, and some were given steroids; the delay in appropriate treatment was probably responsible for the subsequent disability in five patients. However, classical rheumatoid arthritis, not associated with mycoplasmal infection, is a rare complication of CVI [2] . There is also another type of milder non-erosive arthritis/arthralgia, without obvious effusions, and with associated tendonitis that occurs in untreated CVI patients, and which improves rapidly after immunoglobulin therapy [18] . There are no reports of attempts to culture mycoplasmas from synovial fluid or tissue of such patients, although it is interesting that two of our patients (nos 8 and 14) presented initially with this condition, and after improving on immunoglobulin therapy relapsed later with a proven mycoplasmal arthritis. Many patients had previous or subsequent extra-articular 'infections' Numbers in parentheses relating to the antibiotics are minimal inhibitory concentrations for the relevant mycoplasmas or ureaplasmas (mg/ml). *Hyperimmune goat serum obtained by immunizing goats with mycoplasmas cultured from the patient, ultracentrifuged from bulk culture, the deposit washed twice in phosphate-buffered saline, and injected s.c. with Freund's adjuvant. Titres ranged from 1:64 to 1:256 depending on the batch. Rabbits were also immunized, providing sera with titres ranging from 1:16 to 1:64. Table IV. which could not be identified using routine microbiological techniques, and were probably caused by mycoplasmas. It is not known why mycoplasmas have a predilection for joints, but presumably joint fluid contains nutrients to encourage the growth of these organisms. Previous work in vitro has shown that mycoplasmas are taken up by neutrophils into phagocytic vacuoles in the absence of specific antibody [19] . Opsonization is probably achieved by spontaneous activation of the first component of complement. There is evidence that the organisms remain viable within neutrophils, and it is possible that neutrophils are attracted to areas of minor trauma in joints where they release viable mycoplasmas. Minor trauma is probably common in many large joints, and in one of our patients (no. 7) a sporting injury to an ankle and a knee preceded an episode of septic arthritis. Furthermore, the same patient developed mycoplasmal s.c. abscesses at injection sites, suggesting homing of infected phagocytes to areas of minor trauma.
The primary site of infection is not known in the majority of cases, but antibody-deficient patients are prone to mycoplasmal colonization of the urogenital [20, 21] and respiratory tract [22] . Two female CVI patients had suffered from recurrent vaginitis prior to the onset of arthritis, and U. urealyticum and M. hominis were isolated from a vaginal swab taken from one of them. Three of the six female CVI patients had M. hominis or an unidentified arginine-splitting organism cultured from their synovial fluids, while most of the male XLA or CVI patients had ureaplasmas or M. pneumoniae in their joint aspirates. The possible existence of bacterial vaginosis (BV) should be considered in women presenting with M. hominis-induced arthritis. BV is a condition which occurs in about 10% of otherwise normal healthy women. It is characterized by the replacement of lactobacilli by a variety of mainly anaerobic bacteria that appear to enhance the local conditions for growth of M. hominis organisms, so that they are found in the vagina in numbers at least a 1000-fold greater than in healthy women [23] . If vaginosis is present in a patient with M. hominis-induced arthritis, it may be helpful to treat with metronidazole. Most of the patients were adults, and two men had suffered with recurring urethritis, probably sexually acquired, prior to the onset of arthritis. Four XLA patients were under 15 yr of age, and the arthritis in two was probably caused by infection with M. pneumoniae since this was isolated a few years later from a lung lesion in patient no. 5, and a glucose-fermenting mycoplasma was isolated from an adjacent s.c. infection in the other (no. 6). In these cases, the primary infection was probably in the lungs.
Polymerase chain reaction (PCR) techniques have been developed for M. pneumoniae and ureaplasmas, and are likely to be more sensitive than culture. Such techniques should be able to identify the type of mycoplasma involved within 24 h. Since our experience with testing antibiotic sensitivities was not clearly helpful in the management, it could be argued that PCR confirmation, i.v. doxycycline and high-dose i.v. immunoglobulin should be the initial procedures; if this fails, then the empirical use of other antibiotics with hyperimmune animal serum should be considered.
As the current number of patients with CVI and XLA on the UK Registry is 01000, based on our experience we can estimate that such patients have between a 1:20 and 1:55 chance of developing mycoplasmal arthritis at some time in their life. This estimate is in line with previous surveys of arthritis in these patients where no organism has been cultured [30, 31] ; we suggest that many of these cases were probably due to mycoplasmas. However, it is likely that earlier diagnosis of the primary immunodeficiency and more meticulous attention to maintaining IgG levels within the normal range will reduce this risk substantially.
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